中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | HT348076 |
|---|---|
| 種反応性 | Human |
| アプリケーション | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 宿主種 | Human |
| クローン性 | Monoclonal |
| アイソタイプ | (VHH-VHH-hFc)-dimer |
| クローンID | TAS266 |
| 生物学的活性 | TAS266 is up to 1000-fold more potent than cross-linked DR5 antibody or TRAIL at inducing cell death in cancer cell lines via DR5 activation, with faster downstream caspase activation kinetics [1]. TAS266 potently induces death in human tumor cell lines, with potency ≥1000-fold greater than cross-linked DR5 antibody LBY135 or TRAIL [2]. TAS266 (200 mg/kg; twice weekly) shows no target organ toxicity including hepatotoxicity in cynomolgus monkeys after administration, with its biological activity remaining intact [2]. TAS266 (single dose; weekly) induces tumor regression in a variety of tumor xenograft models, and its antitumor activity with weekly administration is superior to that of DR5 agonist antibodies in pancreatic cancer and colon cancer xenograft models [2]. . Maintained bioactivity despite presence of preexisting or treatment-emergent TAS266-binding IgG antibodies in some animals. . Exhibited superior anti-tumor activity compared with a DR5 agonist antibody in patient-derived pancreatic and colon xenograft models. |
| テスト済みアプリケーション | WB |
| ターゲット | CD262, DR5, Death receptor 5, KILLER, TNF-related apoptosis-inducing ligand receptor 2, TNFRSF10B, TRAIL receptor 2, TRAIL-R2, TRAILR2, TRICK2, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9 |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | O14763 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 別名 | TAS266 |
| 背景 | Tumor necrosis factor receptor superfamily member 10B (CD262/TRAIL-R2) is a ~47 kDa protein. Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis. 1. Hymowitz, SG. et al. (1999) Molecular cell 4, 563-71. PMID: 10549288 |
| 参考文献 | 1. Huet H, et al. TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches[J]. Cancer Research, 2012, 72(8_Supplement): 3853-3853. [HT348076] 2. Papadopoulos KP, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015;75(5):887-895. [HT348076] |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307) Human IgG1 (LALA) Recombinant Isotype Control Antibody (HyHEL-10) (HP688107) |
Detects Human CD262/TNFRSF10B/TRAIL-R2/DR5 in indirect ELISAs.
SDS-PAGE for Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (TAS266)
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
